Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain

Deanna Kerrigan, Andrea Mantsios, Miguel Gorgolas, Maria-Luisa Montes, Federico Pulido, Cynthia Brinson, Jerome deVente, Gary J Richmond, Sarah W Beckham, Paige Hammond, David Margolis, Miranda Murray, Deanna Kerrigan, Andrea Mantsios, Miguel Gorgolas, Maria-Luisa Montes, Federico Pulido, Cynthia Brinson, Jerome deVente, Gary J Richmond, Sarah W Beckham, Paige Hammond, David Margolis, Miranda Murray

Abstract

Challenges with adherence to daily oral antiretroviral therapy (ART) among people living with HIV (PLHIV) have stimulated development of injectable long-acting (LA) regimens. We conducted 39 in-depth interviews with participants and providers in a Phase IIb study (LATTE-2) evaluating an injectable LA regimen in the U.S. and Spain. Interviews exploring participant and provider attitudes and experiences with LA versus oral ART were audiotaped, transcribed and analyzed using thematic content analysis. Participants described the convenience of LA injections versus daily pills and emotional benefits such as minimized potential for HIV disclosure and eliminating the "daily reminder of living with HIV." Providers recognized benefits but cautioned that LA candidates still need to adhere to clinic visits for injections and raised questions around ongoing clinical management. LA was seen as preferable to daily oral ART among PLHIV. Further research is needed regarding appropriate candidates, including with women and "non-adherent" populations across settings.

Conflict of interest statement

Competing Interests: Authors DK, AM, SB, and PH received support for this study via a ViiV Healthcare contract; authors MG, MLM, FP, CB, JDV, GJR were investigators on trials supported in part by ViiV Healthcare; authors DM and MM are employees of ViiV Healthcare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products to declare.

References

    1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Fact Sheet 2016. Available from: .
    1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Update 2016. Available from: .
    1. Joint United Nations Programme on HIV/AIDS (UNAIDS). The Gap Report 2014. Available from: .
    1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine. 1998;338(13):853–60. doi:
    1. Li TS, Tubiana R, Katlama C, Calvez V, Mohand HA, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. The Lancet. 1998;351(9117):1682–6.
    1. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. New England Journal of Medicine. 2000;342(13):921–9. doi:
    1. Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2005;40(1):96–101.
    1. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. The Lancet. 2010;375(9731):2092–8.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine. 2011;365(6):493–505. doi:
    1. Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Current Opinion in HIV and AIDS. 2012;7(2):99 doi:
    1. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. The Lancet infectious diseases. 2014;14(4):281–90. doi:
    1. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell M-L. High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966–71. doi:
    1. Das M, Chu PL, Santos G-M, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PloS one. 2010;5(6):e11068 doi:
    1. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. The Lancet. 2010;376(9740):532–9.
    1. Beer L, Heffelfinger J, Frazier E, Mattson C, Roter B, Barash E, et al. Use of and adherence to antiretroviral therapy in a large US sample of HIV-infected adults in care, 2007–2008. The open AIDS journal. 2012;6(1).
    1. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438 doi:
    1. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clinical Infectious Diseases. 2000;30(Supplement 2):S171–S6.
    1. Kagee A, Remien RH, Berkman A, Hoffman S, Campos L, Swartz L. Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Global public health. 2011;6(1):83–97. doi:
    1. Reda AA, Biadgilign S. Determinants of Adherence to Antiretroviral Therapy among HIV-Infected Patients in Africa. AIDS Research and Treatment. 2012;2012:574656 doi:
    1. Gross IM, Hosek S, Richards MH, Fernandez MI. Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV. AIDS Patient Care and STDs. 2016;30(7):324–38. doi:
    1. Mellins CA, Kang E, Leu C-S, Havens JF, Chesney MA. Longitudinal study of mental health and psychosocial predictors of medical treatment adherence in mothers living with HIV disease. AIDS Patient Care and STDs. 2003;17(8):407–16. doi:
    1. Golin CE, Liu H, Hays RD, Miller LG, Beck CK, Ickovics J, et al. A prospective study of predictors of adherence to combination antiretroviral medication. Journal of general internal medicine. 2002;17(10):756–65. doi:
    1. Kacanek D, Angelidou K, Williams PL, Chernoff M, Gadow KD, Nachman S, et al. Psychiatric symptoms and antiretroviral nonadherence in US youth with perinatal HIV: a longitudinal study. AIDS. 2015;29(10):1227–37. doi:
    1. Murray LK, Semrau K, McCurley E, Thea DM, Scott N, Mwiya M, et al. Barriers to acceptance and adherence of antiretroviral therapy in urban Zambian women: a qualitative study. AIDS care. 2009;21(1):78 doi:
    1. Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. Journal of the International AIDS Society. 2013;16(3).
    1. Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care & STDs. 2006;20(5):359–68.
    1. Andrews CD, Heneine W. Cabotegravir long-acting for HIV-1 prevention. Current Opinion in HIV and AIDS. 2015;10(4):258–63. doi:
    1. Margolis DA, Boffito M. Long-acting antiviral agents for HIV treatment. Current Opinion in HIV and AIDS. 2015;10(4):246–52. doi:
    1. Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Current Opinion in HIV and AIDS. 2013;8(6):565–71. doi:
    1. Margolis D, Podzamczer D, Stellbrink H, Lutz T, Angel J, Richmond G, et al., editors. Cabotegravir + rilpivirine as long-acting maintenance therapy: LATTE-2 week 48 results 21st International AIDS Conference (AIDS 2016); 2016; Durban.
    1. Margolis DA, Gonzalez-Garcia J, Stellbrink H-J, Eron J, Yazdanpanah Y, Griffith SK, et al., editors. Cabotegravir+ rilpivirine as long-acting maintenance therapy: LATTE-2 week 32 results. Conference on Retroviruses and Opportunistic Infections (CROI); 2016; Boston.
    1. Guest G, Bunce A, Johnson L. How many interviews are enough? Field Methods. 2006;18(1):59–82.
    1. Patton MQ. Qualitative Research and Evaluation Methods (3rd Edition). United States: Sage Publications; 2002.
    1. Scientific Software Development GmbH. ATLAS.ti 1.0.50 ed. Eden Prairie, MN,2013.
    1. Pope C, Ziebland S, Mays N. Analysing qualitative data. BMJ: British Medical Journal. 2000;320(7227):114–6.
    1. Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115–25.
    1. Nachega JB, Parienti J-J, Uthman OA, Gross R, Dowdy DW, Sax PE, et al. Lower pill burden and once-daily dosing antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clinical Infectious Diseases. 2014:ciu046.
    1. Parienti J-J, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clinical Infectious Diseases. 2009;48(4):484–8. doi:
    1. Robbins RN, Spector AY, Mellins CA, Remien RH. Optimizing ART Adherence: Update for HIV Treatment and Prevention. Current HIV/AIDS reports. 2014;11(4):423–33. doi:
    1. Ware NC, Wyatt MA, Tugenberg T. Social relationships, stigma and adherence to antiretroviral therapy for HIV/AIDS. AIDS Care. 2006;18(8):904–10. doi:
    1. Sayles JN, Wong MD, Kinsler JJ, Martins D, Cunningham WE. The Association of Stigma with Self-Reported Access to Medical Care and Antiretroviral Therapy Adherence in Persons Living with HIV/AIDS. Journal of General Internal Medicine. 2009;24(10):1101 doi:
    1. Friedland GH. HIV Medication Adherence: The Intersection of Biomedical, Behavioral, and Social Science Research and Clinical Practice. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2006;43:S3–S9. doi:

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner